Skip to main
LCTX
LCTX logo

LCTX Stock Forecast & Price Target

LCTX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lineage Cell Therapeutics Inc. is advancing its pipeline of innovative therapies, particularly through its ReSonance program, which focuses on auditory neuron transplant candidates for addressing auditory neuropathy and enhancing cochlear implant effectiveness. The company has successfully progressed to the next preclinical stages with the development of targeted auditory neuronal cell types and the generation of novel intellectual property, achieved with minimal incremental investment. Furthermore, a committed funding of up to $12 million from William Demant Invest provides significant financial backing to support these critical advancements in the company's therapeutic pipeline.

Bears say

Lineage Cell Therapeutics Inc is facing significant challenges due to its reliance on clinical-stage products that have not yet generated revenue or achieved commercial viability, which raises concerns about the sustainability of its funding. The company's development pipeline, while innovative, is still in early stages, with OpRegen and other therapies undergoing clinical trials that inherently carry risks of delays or failures, impacting investor confidence. Additionally, the competitive landscape in biotechnology and the need for substantial capital infusion for continued research and development further contribute to a negative outlook on the company's financial viability.

LCTX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lineage Cell Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lineage Cell Therapeutics Inc (LCTX) Forecast

Analysts have given LCTX a Strong Buy based on their latest research and market trends.

According to 4 analysts, LCTX has a Strong Buy consensus rating as of Nov 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lineage Cell Therapeutics Inc (LCTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.